Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

Viral Infections, Non-HIV

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

doi: 10.1126/science.abc1560.

Viral Infections, Non-HIV

The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro

doi: 10.1016/j.antiviral.2020.104787.

Viral Infections, Non-HIV

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Clin Infect Dis.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D

doi: 10.1093/cid/ciaa237.

Viral Infections, Non-HIV

A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of Viral/Nicotinic Acetylcholine Receptor Complexes

Med Sci Monit.

Stefano ML, Kream RM, Stefano GB

doi: 10.12659/MSM.926016.

Viral Infections, Non-HIV

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

N Engl J Med.

van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JO, de Wit E, Munster VJ

doi: 10.1056/NEJMc2004973.

Viral Infections, Non-HIV

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Nature.

Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, van Doremalen N, Leighton I, Yinda CK, Pérez-Pérez L, Okumura A, Lovaglio J, Hanley PW, Saturday G, Bosio CM, Anzick S, Barbian K, Cihlar T, Martens C, Scott DP, Munster VJ, de Wit E

doi: 10.1038/s41586-020-2423-5.

Viral Infections, Non-HIV

Clofazimine broadly inhibits coronaviruses including SARS-CoV-2

Nature

Yuan S, Yin X, Meng X, Chan JF, Ye ZW, Riva L, Pache L, Chan CC, Lai PM, Chan CC, Poon VK, Lee AC, Matsunaga N, Pu Y, Yuen CK, Cao J, Liang R, Tang K, Sheng L, Du Y, Xu W, Lau CY, Sit KY, Au WK, Wang R, Zhang YY, Tang YD, Clausen TM, Pihl J, Oh J, Sze KH, Zhang AJ, Chu H, Kok KH, Wang D, Cai XH, Esko JD, Hung IF, Li RA, Chen H, Sun H, Jin DY, Sun R, Chanda SK, Yuen KY

doi: 10.1038/s41586-021-03431-4

Viral Infections, Non-HIV

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

Viruses.

Ahmed SF, Quadeer AA, McKay MR

doi: 10.3390/v12030254.

Viral Infections, Non-HIV

Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals

Nature.

Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, Sun L, Duan Y, Cai J, Westerdahl D, Liu X, Xu K, Ho KF, Kan H, Fu Q, Lan K

doi: 10.1038/s41586-020-2271-3.

Related content

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of Viral/Nicotinic Acetylcholine Receptor Complexes

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Clofazimine broadly inhibits coronaviruses including SARS-CoV-2

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals